554 results about "Treatment use" patented technology

Related to macrocyclic compounds and therapeutic uses thereof. Disclosed a compound of formula (I), or a pharmaceutically acceptable salt thereof, a solvate thereof or a solvate of the pharmaceutically acceptable salt, and their use for the preparation of a medicament of treatment of cancer. Provided herein are useful compounds for the inhibition of RAS mutant and the compound shows good inhibitory activity against RAS.

There is provided a fluorinase variant thereof having at least 70% sequence identity to a sequence MSDLGX6TDDSVAQCKGLMLSICPX24VX26IX28DX30CHX33MTPX37DVVEGARYIVDLPR X52FPEGTVFATTTYPATGTX70X71RSVAX76RX78KX80AALGGARGQX90AGSGX95GX97E RAEGX103YIYIAPNNGLLTX116VIEEHGYX124EAYEVSX131TX133VIPX137X138PEPTFYSR EMVAIPSAHLAAGFPLX163X164VGRX168LX170DX172EIVRFEX179X180KX182X183X184VX186G X188X189LX191GX193X194X195X196X197DHPFGNX204WTNX208HRTDLEKAGIX219YX221TX223X 224KX226VX228DGVLX233FX235LPLX239PTFADAX246X247X248GX250PVX253YX255NSRGYLX2 62X263ARNAAX269LAYPYNLX277AGX280SVX283VTX286A (SEQ ID NO: 1), wherein X is a natural amino acid, and wherein the variant comprises one or more mutations at a site selected from the group consisting of an ion-egress site, a S-Adenosyl-L-Methionine (SAM) binding site, an ion-binding site (IBS), and a conserved site. Also disclosed are polynucleotides encoding the variants, vectors comprising the polynucleotides encoding the variants, and host cells comprising the vectors thereof. Also disclosed are Methods for producing the variants, methods of catalyzing the fluorination of a compound, uses of the fluorinase variants, and methods of treatment using the fluorinase variants thereof.

An improved machine learning based method for authorizing the performance of a treatment, comprising the steps of: receiving a treatment authorization request, the treatment authorization request including a historical record of the person who will receive the treatment and treatment identifying information relating to the treatment; creating an extracted text of the historical record using optical character recognition on the historical record; determining whether to analyze authorization performance of the treatment using a machine learning authorization process, wherein the determination is based on treatment identifying information and whether treatment authorization guidelines exist for the identified treatment; in response to a determination to analyze authorization performance of the treatment using a machine learning authorization process: identifying authorization criteria for the treatment based on the treatment authorization guidelines, wherein the authorization criteria includes records data conditional to authorization of performance of the treatment; identifying a natural language record processing model corresponding to the expense authorization guidelines; and performing natural language processing on the extracted text of the record in accordance with the identified natural language record processing model to identify relevant record data in the record; determining whether the relevant record data meets the authorization criteria and in response to a determination that the relevant record data meets the authorization criteria, authorizing the performance of the treatment.

The present invention relates to a macrocyclic compound and a therapeutic use thereof. Disclosed in the present invention is a compound of formula (I), a pharmaceutically acceptable salt of said compound, a solvate of said compound, or a solvate of said pharmaceutically acceptable salt, and a use thereof in the preparation of a drug for treating cancer.

Provided is a mammalian-derived cell model that can be used in anti-aging drugs. The mammalian-derived extraembryonic trophoblast cell model is an early mammalian-derived extraembryonic stage. A change model and an aging evaluation index system for differentiating the cells into the extraembryonic trophoblast cells / organoids can be used for various anti-aging researches and target detection, anti-aging drug detection, screening and identification, research on innovative drugs / natural products, and development of chemicals and / or health foods and additives. Screening and identifying many resistances is helpful. Candidate targets of aging may be further mechanically and functionally validated for future therapeutic use. The screening of anti-aging drugs or natural products will produce huge economic and social benefits.

The present invention relates to a new method for assessing acceptability ranges or cut-offs for the compliance validation of batches of products comprising or consisting of one or more natural matrix, wherein said products have an ascertained therapeutic or beneficial effect. The invention also relates to a new process for the compliance validation of one or more batches of said products.

Disclosed herein are compounds of Formula (I) or pharmaceutically acceptable salts thereof: wherein R1 and R2 independently represent a hydrogen atom or a deuterium atom; r3'and R3 ''independently represent a hydrogen atom, a methyl group, a methoxyl group, a chlorine atom, a fluorine atom, or a cyano group; r4 represents a hydrogen atom or a fluorine atom; r5 and R5'independently represent a hydrogen atom or a fluorine atom; y represents-CH2-,-CH =,-CR9 =,-O-or-NH-wherein R9 represents a fluorine atom or a (C1-C3) alkyl group; represents a single bond or a double bond; p is 0 or 1; x represents-CH =,-N = or-CR ''= wherein R'' represents a (C1-C3) alkyl or halogen atom, a cyano group, or a (C1-C3) fluoroalkyl group; r7 independently represents a (C1-C3) alkyl group, a halogen atom, a cyano group, or a (C1-C3) fluoroalkyl group; n is 0, 1 or 2; and R6 represents a (C1-C6) alkyl group, said alkyl group being optionally substituted; r8 represents a hydrogen atom, a (C1-C3) alkyl group, a-CH2F group, a-CHF2 group, a-CF3 group, or a (C3-C4) cycloalkyl group. Further disclosed are processes for preparing the same, pharmaceutical compositions comprising the same and the compounds of formula (I) for use as inhibitors and degrading agents of estrogen receptors, in particular for use in the treatment of ovulation dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hyperplasia or inflammation. # imgabs0 #

A method for authorizing a treatment may include receiving a treatment authorization request, creating an extracted text of a historical record using optical character recognition on the historical record, determining whether to analyze authorization performance of the treatment using a machine learning authorization process, in response to a determination to analyze authorization performance of the treatment using a machine learning authorization process: identifying authorization criteria for the treatment based on treatment authorization guidelines; identifying a natural language record processing model corresponding to expense authorization guidelines, and performing natural language processing on the extracted text of the record in accordance with the identified natural language record processing model to identify relevant record data in the record, determining whether the relevant record data meets the authorization criteria and in response to a determination that the relevant record data meets the authorization criteria, authorizing the performance of the treatment.

The disclosure provides methods for preparation of carbohydrate replacement therapies (CRT) that include nanocarriers of carbohydrates and glycolipids for pharmaceutical delivery to cell interior, endoplasmic reticulum, and Golgi for treating CDG type I and CDG type II diseases as well as other metabolic disorders.

The present invention relates to macrocyclic compounds and therapeutic uses thereof. Disclosed are compounds of formula (I), or pharmaceutically acceptable salts thereof, solvates thereof or solvates of the pharmaceutically acceptable salts, and their use in the preparation of medicaments for the treatment of cancer.

The present disclosure relates to the field of nuclear imaging and therapy, and more specifically to high purity copper radiotracer compositions useful in imaging, such as positron emission tomography (PET) and single-photon emission computerized tomography (SPECT), and therapy. More specifically, the present disclosure relates to novel compositions useful in imaging and treatment of conditions such as prostate cancer, somatostatin receptor-expressing tumors, like neuroendocrine tumor, epithelial tumors, as well as to methods wherein such compositions are prepared.

The invention relates to methods for treating a cancer patient comprising administering a Zn(II) agent or a Zn(II) agent / immune-oncology agent combination to provide a therapeutic benefit to the cancer patient. The methods are useful in treating a broad spectrum of human cancers, including solid tumors and blood-based cancerous cells. In particular embodiments, the treatment methods are directed to cancer types characterized by genetic instability mutations.

Various methods, devices, and systems for task identification and resource management are described. In one aspect, a method includes obtaining information about a subject, obtaining identification of a condition of the subject based on the information, and obtaining identification of a treatment for the subject. The method also includes identifying a set of tasks corresponding to the treatment, generating, via a rules engine, a first set of parameters for the tasks, and generating, via an artificial intelligence (AI) engine, a second set of parameters for the tasks. The method further includes generating a resource allocation schedule for the treatment using the set of tasks, first set of parameters, and the second set of parameters, including assigning one or more tasks to a particular entity, and providing information about the one or more tasks to the particular entity.

Compositions comprising a first polypeptide comprising a first fragment of an N-terminal extracellular domain of TSHR or an analog or derivative thereof and a dimerization domain and a second polypeptide comprising a second fragment of an N-terminal extracellular domain of TSHR or an analog or derivative thereof and a dimerization domain are provided. Polypeptides comprising fragments of an N-terminal extracellular domain of TSHR comprising at least one mutation that increases solubility, decreases aggregation or both are also provided. Pharmaceutical compositions comprising the composition, polypeptide, nucleic acid systems and molecules encoding the polypeptides of the composition and invention and methods of treatment and determining suitability for treatment using the compositions or polypeptides; as well as methods of producing the compositions or proteins are also provided.

The example systems, methods, and / or computer-readable media described herein help with design treatment plans for orthodontic treatments. Treatment templates reflecting a user's treatment preferences are expressed in a domain-specific treatment language and include treatment protocols. Orthodontic treatment plans are customized based on the treatment templates and a physical condition of the patient. Treatment appliances are fabricated based on the customized orthodontic treatment plans.

Disclosed are systems and methods for building and using a data platform to perform intelligent treatment selection to assist in clinical decision making. The present disclosure relates to a server configured to transform a subject record, which characterizes various non-numerical features of a subject, into a transformed representation that is consumable by machine-learning or artificial intelligence models. The output of the machine-learning or artificial-intelligence models can be evaluated to enable the intelligent treatment selection and other enhanced analyses, such as, for example, automatically detecting and defining subject populations, predicting treatment protocols with likely positive responsiveness, and identifying the similarity or dissimilarity between subject records along one or more dimensions.

A system trains a set of machine-learning models to predict which atrial fibrillation patients would respond to which treatments using ablation lines. The models identify an ablation line treatment for a patient based on atrial fibrillation-related features associated with the patient. The models estimate reconnection probabilities for ablation sites associated with at least one ablation line treatment. The models identify patient atrial fibrillation predictors associated with the patient, based on demographics and heart component dimension parameters associated with the patient, and use the at least one ablation line treatment, reconnection probabilities, patient atrial fibrillation predictors, and patient demographics to predict whether the patient would not respond to pulmonary vein isolation only treatment. In response to a prediction that the patient would not respond to pulmonary vein isolation only treatment, the system enables a healthcare provider to provide the at least one ablation line treatment for the patient.

The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, tautomers or stereoisomers and solvates thereof, which are useful in the treatment of cancer and inflammation in mammals. The invention also discloses a preparation method of the compound shown in the formula (I) and a pharmaceutical composition containing the compound. # imgabs0 #

The present disclosure provides compounds, compositions containing such compounds, and methods of designing, developing, producing and preparing compounds represented by general Formula (I), including pharmaceutically acceptable salts thereof or a synthetic intermediate thereof:The compounds act as MEK inhibitors and are capable of displaying one or more beneficial therapeutic effects, including treating cancer.

Compositions comprising two pHLIP® peptides linked to a STING agonist, which is a dimer with a carboxylic acid subsituent (carboxyl group) at the terminal position of both monomers of the dimer, pharmaceutical compositions thereof, and methods of treatment using such compositions are disclosed herein.

The present disclosure relates to the field of nuclear imaging and therapy, and more particularly, to high purity copper radiotracer compositions that can be used in imaging (e.g., positron emission tomography (PET) and single photon emission computed tomography (SPECT)) and therapy. More specifically, the present disclosure relates to novel compositions useful for imaging and treating conditions (e.g., prostate cancer, somatostatin receptor expressing tumors, such as neuroendocrine tumors, epithelial tumors), and methods of making such compositions.

As described below, the present invention features compositions, panels of biomarkers, and methods for selecting a subject with chronic lymphocytic leukemia (CLL) for treatment using an agent and / or for inclusion in a clinical trial using the agent to treat CLL.

The present invention relates to a pharmaceutical combination product and a therapeutic use thereof. Specifically, the present invention provides a pharmaceutical combination product comprising a first pharmaceutically active ingredient and a second pharmaceutically active ingredient, wherein the first pharmaceutically active ingredient is a KRAS inhibitor. The present invention also provides a use for treating tumors, comprising administering the pharmaceutical combination product of the present invention to a subject in need.

The present application relates, inter alia, to anti-cMET antibody drug conjugates ("ADC") ("pH-ADC") having lower target-specific binding at lower pH relative to physiological pH; a pharmaceutical composition including the pH-ADC; a method for preparing the pH-ADC; methods of selecting a specific patient population for cancer treatment with an anti-cMET pH-ADC; the present invention relates to pH-ADCs, and methods of using the pH-ADCs in the treatment of cancer, including cMET + / cMET-expressing or overexpressing cancers, in particular non-small cell lung cancer ("NSCLC"), including cMET + / cMET-expressing or overexpressing cMET.

The present invention relates to a compound of the formula (i) wherein Ar represents a phenyl or a 6-membered heteroaryl group, R1 and R2 represent independently a hydrogen atom or a deuterium atom, R3 represents (1) a —COR4 group, (2) a —BOR5OR6 group, (3) a —X—Z group, (4) a (C1-C6)alkyl group or a (C1-C6)alkenyl group, (5) a —X—S(O)n(R7)p(R8)q group, (6) a halogen atom, a —NH2 group or a —CN group, (7) a —O—R11 group, (8) a —NH—COR9 group, (9) a —C(═NH)NHOH group, (10) a —NH—C(NH)—R9′ group, or (11) a —NHCOCOOR12 group or a —NHCOCONR12′R12″ group, X represents a bond, a —NH— group, a —CONH— group or a —CO— group, Z represents a 4 or 5-membered cycloalkyl, a 4 or 5-membered heterocylcloalkyl group, a 4 or 5-membered heteroaryl group or a phenyl group or a pharmaceutically acceptable salt thereof. The present invention further relates to a medicament comprising said compound of formula (I) and to said compound of formula (I) for use as an inhibitor and degrader of estrogen receptors.

In some aspects, the present disclosure provide systems for forming crosslinked reaction products, which comprise (a) a first composition that comprises a first multifunctional molecule that comprises a plurality of first reactive moieties that comprise oxyamine groups and (b) a second composition that comprises a second multifunctional molecule that comprises a plurality of second reactive moieties that comprise aldehyde or ketone groups, wherein at least one of the first and second multifunctional molecules is a multi-arm polymer and wherein at least one of the first and second multifunctional molecules comprises one or more covalently attached iodine groups. Other aspects of the present disclosure pertain to crosslinked networks that are formed using such systems and methods of treatment using such systems.

A method is provided for coordinated wellness treatments using a plurality of PBM devices. The method includes collecting wellness data from each PBM device; transmitting the collected wellness data to a server; analyzing the wellness data to generate personalized treatment recommendations; recording the wellness data and treatment recommendations onto a distributed ledger system; communicating the personalized treatment recommendations to each PBM device; and adjusting the PBM treatments based on the personalized recommendations.